TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39122384

Group type: EXPERIMENTAL
Intervention: Lactoferrin
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Lysozyme
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Combination of lactoferrin and lysozyme
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 39122389

Group type: EXPERIMENTAL
Intervention: Dose-volume constraints derived from statistical model in PredicT A
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dose-volume constraints tested in PredicT B
Number of subjects: 150
Study: 39122392

Group type: EXPERIMENTAL
Intervention: Empowered Relief (ER)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Living Better (control)
Number of subjects: 0
Study: 39122402

Group type: EXPERIMENTAL
Intervention: Cy-Tb skin test
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Standard F TB assay
Number of subjects: 350

Group type: COMPARATOR
Intervention: QFT-Plus assay
Number of subjects: 350
Study: 39122404

Group type: EXPERIMENTAL
Intervention: KECHI plus usual care
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study: 39122403

Group type: EXPERIMENTAL
Intervention: Usual care plus access to supplemental speech-language teletherapy
Number of subjects: 210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study: 39122636

Group type: EXPERIMENTAL
Intervention: Surgery (cordectomy)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 41
Study: 39122650

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 0
Study: 39122717

Group type: EXPERIMENTAL
Intervention: Blinatumomab after R-CHOP induction
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Overall strategy including R-CHOP and blinatumomab
Number of subjects: 39
Study: 39122726

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, trastuzumab, and bevacizumab
Number of subjects: 36
Study: 39122788

Group type: EXPERIMENTAL
Intervention: m-DOT (mobile Directly Observed Therapy) with hydroxyurea (15 mg/kg daily for three months)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard monitoring with hydroxyurea (15 mg/kg daily for three months)
Number of subjects: 86
Study: 39122804

Group type: EXPERIMENTAL
Intervention: Male partner-targeted breastfeeding education and support interventions
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 408
Study: 39123054

Group type: EXPERIMENTAL
Intervention: Lebrikizumab every 2 weeks (Q2W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lebrikizumab every 4 weeks (Q4W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lebrikizumab withdrawal (placebo Q2W)
Number of subjects: 0
Study: 39123126

Group type: EXPERIMENTAL
Intervention: Non-invasive biomarkers of airway disease, Barrett's Esophagus, and gastroesophageal reflux disease (GERD)
Number of subjects: 4192

Group type: COMPARATOR
Intervention: Sub-cohort control group
Number of subjects: 4192
Study: 39123146

Group type: EXPERIMENTAL
Intervention: Prehabilitation program (4-6 weeks duration)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no prehabilitation)
Number of subjects: 68
Study: 39123200

Group type: EXPERIMENTAL
Intervention: Independent Supported Housing (ISH)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Housing rehabilitation as usual (HAU)
Number of subjects: 83
Study: 39123210

Group type: EXPERIMENTAL
Intervention: Chiauranib combined with etoposide (CE group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chiauranib combined with weekly-paclitaxel (CP group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Chiauranib monotherapy (phase Ib study)
Number of subjects: 43
Study: 39123434

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (docetaxel, cisplatin, and 5-fluorouracil)
Number of subjects: 224
Study: 39124551

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39124613

Group type: EXPERIMENTAL
Intervention: Coregistration with iFR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 39125394

Group type: EXPERIMENTAL
Intervention: Teduglutide (0.05 mg/kg/day)
Number of subjects: 1411

Group type: COMPARATOR
Intervention: Parenteral nutrition and/or intravenous fluids (mean volume)
Number of subjects: 1411
Study: 39125451

Group type: EXPERIMENTAL
Intervention: Glycocalyx dietary supplement (GDS), n = 25
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo, n = 25
Number of subjects: 50
Study: 39126603

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) formulation of donepezil at doses of 70, 140, and 280 mg
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oral formulation of donepezil at 10 mg
Number of subjects: 92
Study: 39126720

Group type: EXPERIMENTAL
Intervention: Clazosentan (15 mg/hour intravenous)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study: 39126937

Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Melatonin 3 mg daily
Number of subjects: 30
Study: 39127063

Group type: EXPERIMENTAL
Intervention: Imatinib continuation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Imatinib interruption
Number of subjects: 32
Study: 39127450

Group type: EXPERIMENTAL
Intervention: BCG-Denmark (n = 1999)
Number of subjects: 3988

Group type: COMPARATOR
Intervention: Saline (placebo group, n = 1989)
Number of subjects: 3988
Study: 39127622

Group type: EXPERIMENTAL
Intervention: Surgeon-performed adductor canal block (ACBs)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided adductor canal block (ACBa)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (no adductor block)
Number of subjects: 240
Study: 39127709

Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResNet 18 for diagnosing CAN
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResNet 18 for distinguishing definite or severe stages of CAN (dsCAN)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: AI-based deep learning techniques using ResWide 50 for diagnosing dsCAN
Number of subjects: 229
Study: 39127745

Group type: EXPERIMENTAL
Intervention: Atezolizumab in combination with chemotherapy with or without bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiographic assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal ctDNA parameters
Number of subjects: 0
Study: 39127813

Group type: EXPERIMENTAL
Intervention: HPG/HA lubricant eye drops
Number of subjects: 70

Group type: COMPARATOR
Intervention: CMC/HA lubricant eye drops
Number of subjects: 70
Study: 39127924

Group type: EXPERIMENTAL
Intervention: StemMACS (Miltenyi Biotec)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRIME-XV (FUJIFILM Irvine Scientific)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FBS-containing culture conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HALPCs cultured in SFM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HALPCs
Number of subjects: 0
Study: 39128143

Group type: EXPERIMENTAL
Intervention: Culturally adapted multisensory intervention combining Snoezelen, aromatherapy, and personal items
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 39128497

Group type: EXPERIMENTAL
Intervention: Avocado-supplemented group (AVO, usual diet with 1 avocado/d)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Habitual diet group (HAB, usual diet with limited avocado intake)
Number of subjects: 994
Study: 39128498

Group type: EXPERIMENTAL
Intervention: Methionine test intake (range: 0-40 mg⋅kg) during early gestation (11-20 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Methionine test intake (range: 0-40 mg⋅kg) during late gestation (31-40 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Current DRI recommendations for TSAA during pregnancy
Number of subjects: 25
Study: 39128547

Group type: EXPERIMENTAL
Intervention: Erythrocyte VLCSFAs (C20:0, C22:0, C24:0)
Number of subjects: 2383

Group type: EXPERIMENTAL
Intervention: Higher total VLCSFA concentrations
Number of subjects: 2383
Study: 39128590

Group type: EXPERIMENTAL
Intervention: Lanadelumab 300 mg every 2 weeks
Number of subjects: 21
Study: 39128904

Group type: EXPERIMENTAL
Intervention: Neoantigen DNA vaccine
Number of subjects: 9
Study: 39128918

Group type: EXPERIMENTAL
Intervention: AKL-T01 digital therapeutic
Number of subjects: 221
Study: 39129005

Group type: EXPERIMENTAL
Intervention: Oral Myofunctional Therapy (OMT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control Group (CPAP and MAD)
Number of subjects: 39
Study: 39129017

Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (intraoral camera)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (smartphone camera)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Referral pathways (user fee removal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Referral pathways (conventional care)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (intraoral camera) and referral pathways (user fee removal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tele-dentistry detection methods (smartphone camera) and referral pathways (user fee removal)
Number of subjects: 0
Study: 39129149

Group type: EXPERIMENTAL
Intervention: SNAP participation
Number of subjects: 287
Study: 39129266

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (raloxifene)
Number of subjects: 0
Study: 39129524

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) palliative care intervention
Number of subjects: 0
Study: 39129619

Group type: EXPERIMENTAL
Intervention: Lugol solution (7 days treatment)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No Lugol treatment (control group)
Number of subjects: 56
Study: 39129649

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 39129821

Group type: EXPERIMENTAL
Intervention: Intervention delivered by an intermediary to improve physical activity levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: International Physical Activity Questionnaire - Short Form
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Self-Efficacy for Exercise Scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Short Warwick Edinburgh Mental Well-being Scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Semi-structured interviews
Number of subjects: 30
Study: 39129921

Group type: EXPERIMENTAL
Intervention: Vitamin A levels in cord blood
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Vitamin D levels in cord blood
Number of subjects: 140
Study: 39130023

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) detectable in 80.7% of patients; median hs-cTnT 10 ng/L (IQR: 6-18 ng/L)
Number of subjects: 1687
Study: 39130025

Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy for AF in cancer patients
Number of subjects: 1514
Study: 39130048

Group type: EXPERIMENTAL
Intervention: Persistently high hs-CRP
Number of subjects: 10460

Group type: COMPARATOR
Intervention: Persistently low hs-CRP
Number of subjects: 10460

Group type: EXPERIMENTAL
Intervention: Elevated (increased) hs-CRP
Number of subjects: 10460

Group type: EXPERIMENTAL
Intervention: Reduced hs-CRP
Number of subjects: 10460
Study: 39130140

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL) as an adjunct to coronary stenting
Number of subjects: 0
Study: 39130192

Group type: EXPERIMENTAL
Intervention: Socioecological factors (environmental, interpersonal, and individual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in eating behaviors (EB) and physical activity (PA)
Number of subjects: 0
Study: 39130760

Group type: EXPERIMENTAL
Intervention: Machine learning model for predicting Endoscopic Mayo Score (eMS)
Number of subjects: 249
Study: 39130768

Group type: EXPERIMENTAL
Intervention: Mild-to-moderate COVID-19 patients
Number of subjects: 110

Group type: COMPARATOR
Intervention: Severe COVID-19 patients
Number of subjects: 110
Study: 39131140

Group type: EXPERIMENTAL
Intervention: Erlotinib 75 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erlotinib 50 mg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Erlotinib 25 mg/day
Number of subjects: 25
Study: 39131144

Group type: EXPERIMENTAL
Intervention: Oral 8 mg insulin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 39131150

Group type: EXPERIMENTAL
Intervention: 100% oxygen via nonrebreather mask
Number of subjects: 8
Study: 39131473

Group type: EXPERIMENTAL
Intervention: Impella-supported HRPCI
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Complete revascularization during HRPCI
Number of subjects: 406
Study: 39131596

Group type: EXPERIMENTAL
Intervention: Prophylactic drainage (DG)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Non-drainage (NDG)
Number of subjects: 232
Study: 39131668

Group type: EXPERIMENTAL
Intervention: Colesevelam administered with mixed meal tests
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BAM patients without colesevelam
Number of subjects: 12
Study: 39131711

Group type: EXPERIMENTAL
Intervention: Risankizumab 600-mg induction therapy
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Risankizumab (various doses)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 39131784

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with the ClotTriever System
Number of subjects: 500
Study: 39132049

Group type: COMPARATOR
Intervention: Canocapavir 25 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 75 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 150 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 300 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 450 mg
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 75 mg (multiple ascending dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 150 mg (multiple ascending dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Canocapavir 300 mg (multiple ascending dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 39132068

Group type: EXPERIMENTAL
Intervention: LCR1-LCR2
Number of subjects: 3520
Study: 39132075

Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD) (<10 g fiber per day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-residue diet (LRD)
Number of subjects: 28
Study: 39132187

Group type: EXPERIMENTAL
Intervention: Prescription Digital Therapeutic (PDT) containing cognitive behavioral therapy for 90 days
Number of subjects: 22
Study: 39132335

Group type: EXPERIMENTAL
Intervention: One-month dual antiplatelet therapy (DAPT)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Non-Asian cohort
Number of subjects: 273
Study: 39132368

Group type: EXPERIMENTAL
Intervention: Sirolimus target-eluting stent
Number of subjects: 196

Group type: COMPARATOR
Intervention: Everolimus-eluting stent
Number of subjects: 196
Study: 39132396

Group type: EXPERIMENTAL
Intervention: Impella and Saranas Early Bird Bleed Monitoring System (EBBMS)
Number of subjects: 184
Study: 39132400

Group type: EXPERIMENTAL
Intervention: Suture-mediated closure using the Aortix pMCS device
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Standardized steps for suture-mediated closure
Number of subjects: 21
Study: 39132473

Group type: EXPERIMENTAL
Intervention: 1 session of multi-voxel neuro-reinforcement
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 3 sessions of multi-voxel neuro-reinforcement
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 sessions of multi-voxel neuro-reinforcement
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control phobia (not specified intervention)
Number of subjects: 23
Study: 39132483

Group type: EXPERIMENTAL
Intervention: Community-level intervention
Number of subjects: 629
Study: 39132523

Group type: EXPERIMENTAL
Intervention: High-risk pulmonary embolism patients
Number of subjects: 1517
Study: 39132922

Group type: EXPERIMENTAL
Intervention: Prefabricated contoured foot orthoses
Number of subjects: 27

Group type: COMPARATOR
Intervention: Flat shoe inserts
Number of subjects: 27
Study: 39132937

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study: 39132946

Group type: EXPERIMENTAL
Intervention: Mindful Awareness Practices (MAPs)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Survivorship Education (SE)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 247
Study: 39132982

Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine regimen 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39133200

Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: secukinumab 150 mg
Number of subjects: 207
Study: 39133306

Group type: EXPERIMENTAL
Intervention: ipilimumab and nivolumab
Number of subjects: 100
Study: 39133438

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue scale
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score increase
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score change
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue score severity bands
Number of subjects: 586
Study: 39133474

Group type: EXPERIMENTAL
Intervention: Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Oral aspirin, 81 mg, once daily
Number of subjects: 1015

Group type: COMPARATOR
Intervention: Comparison of apixaban vs aspirin among those with cancer
Number of subjects: 1015
Study: 39133505

Group type: EXPERIMENTAL
Intervention: ESC
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1305
Study: 39133532

Group type: EXPERIMENTAL
Intervention: HOLA intervention
Number of subjects: 30
Study: 39133680

Group type: EXPERIMENTAL
Intervention: Standardized pain medication tapering program
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Personalized pain medication tapering program
Number of subjects: 195

Group type: COMPARATOR
Intervention: No tapering program
Number of subjects: 195
Study: 39133774

Group type: EXPERIMENTAL
Intervention: Interleukin-1 Blockade with RPH-104 (Goflikicept)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39133806

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab and ipilimumab (CaboNivoIpi)
Number of subjects: 11
Study: 39133883

Group type: EXPERIMENTAL
Intervention: SCA2 carriers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SCA7 carriers
Number of subjects: 40

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 40
Study: 39133915

Group type: EXPERIMENTAL
Intervention: EMA design factors (number of questions per survey, number of EMAs per day, EMA prompting schedule, payment type, EMA response scale type)
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Older adults, those without a history of substance use problems, and those without current depression
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: App usability
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Overall EMA completion
Number of subjects: 411
Study: 39133921

Group type: EXPERIMENTAL
Intervention: venetoclax-azacitidine
Number of subjects: 392

Group type: COMPARATOR
Intervention: placebo-azacitidine
Number of subjects: 392
Study: 39133923

Group type: EXPERIMENTAL
Intervention: Prior SARS-CoV-2 infection
Number of subjects: 10094

Group type: COMPARATOR
Intervention: Uninfected participants
Number of subjects: 10094

Group type: EXPERIMENTAL
Intervention: PASC index ≥12
Number of subjects: 10094

Group type: COMPARATOR
Intervention: PASC index = 0
Number of subjects: 10094
Study: 39134021

Group type: EXPERIMENTAL
Intervention: Imagined movements in parietal cortex
Number of subjects: 0
Study: 39134085

Group type: EXPERIMENTAL
Intervention: Intraurethral LBP-EC01 (2 days) and intravenous LBP-EC01 (1×10) for 3 days
Number of subjects: 39
Study: 39134086

Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy (up to 74 Gy)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard radiotherapy (66 Gy)
Number of subjects: 158
Study: 39134120

Group type: EXPERIMENTAL
Intervention: Isatuximab (anti-CD38 monoclonal antibody)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Daratumumab (anti-CD38 monoclonal antibody)
Number of subjects: 26
Study: 39134144

Group type: EXPERIMENTAL
Intervention: Decídetexto
Number of subjects: 457

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 457
Study: 39134156

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: MBSR
Number of subjects: 67
Study: 39134346

Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blockade of TIM-3 and PD-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supplement of anti-TIM-3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor and paired lung samples from treatment-naïve patients
Number of subjects: 0
Study: 39134391

Group type: EXPERIMENTAL
Intervention: Stopping infliximab
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Biomarker pairs (top 10)
Number of subjects: 202
Study: 39134434

Group type: EXPERIMENTAL
Intervention: Low-dose sesame oral immunotherapy (OIT) with a 300 mg maintenance dose of sesame protein administered once daily for up to 18 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment including an elimination diet and observation for 1 year
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Low-dose sesame oral immunotherapy (OIT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment including an elimination diet
Number of subjects: 39